Compounding HRT Solutions for Women’s Hormonal Health

According to NIH MedlinePlus and ACOG, in women's hormonal health, irregular periods may present as unpredictable changes in menstrual cycle length, flow volume, or timing. Cycles may be shorter or longer than a woman's usual pattern; bleeding may be lighter or heavier, and unexpected spotting or skipped cycles may occur. According to ACOG, these changes are commonly associated with the hormonal fluctuations of perimenopause, during which estrogen and progesterone levels shift unpredictably before ovarian function ceases. Patients experiencing persistent cycle irregularities, heavy bleeding, or intermenstrual bleeding should seek evaluation from a qualified clinician, as these symptoms may indicate underlying gynecologic or endocrine conditions requiring assessment.

According to NIH MedlinePlus and NAMS (The Menopause Society), hot flashes are a vasomotor symptom commonly associated with declining estrogen levels during perimenopause and menopause. They may present as sudden sensations of warmth, most intense over the face, neck, and chest, often accompanied by flushing and perspiration, and may be followed by chills. According to NAMS, hot flashes may vary in frequency and severity and may disrupt sleep when they occur at night. Patients experiencing severe or frequent vasomotor symptoms should seek evaluation from a qualified clinician; sudden onset of severe symptoms may indicate conditions requiring prompt medical assessment.

According to NIH MedlinePlus and ACOG, mood changes — including irritability, tearfulness, and heightened anxiety — are commonly associated with hormonal fluctuations in estrogen and progesterone during the menstrual cycle, perimenopause, postpartum periods, and other reproductive transitions. According to ACOG, these shifts may reflect the influence of reproductive hormones on neurotransmitter systems and may be accompanied by changes in energy, sleep quality, and concentration. Patients experiencing mood disturbances that significantly disrupt daily functioning, work, or relationships should seek evaluation from a qualified clinician, as these symptoms may indicate a mood disorder or other condition warranting clinical assessment and management.

According to NIH MedlinePlus and the Endocrine Society Clinical Practice Guideline, gradual weight gain — particularly increased fat mass around the abdomen — may occur in association with hormonal changes during perimenopause and menopause. According to the Endocrine Society Clinical Practice Guideline, shifts in estrogen levels may influence fat distribution and metabolic rate, contributing to changes in body composition that persist even when diet and activity remain unchanged. This weight change may coexist with persistent bloating, altered appetite, low energy, and changes in menstrual patterns. Patients experiencing unexplained weight gain should seek evaluation from a qualified clinician, as this symptom may indicate thyroid dysfunction, insulin resistance, or other endocrine conditions requiring assessment.

According to the FDA-approved prescribing information for Prometrium, Prometrium is an oral micronized progesterone indicated for the prevention of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated equine estrogen tablets, and for use in secondary amenorrhea. According to the FDA-approved prescribing information for Prometrium, the labeling describes Prometrium as replicating the activity of endogenous progesterone and notes that it may be dosed cyclically or continuously depending on clinical goals. According to the FDA-approved prescribing information for Prometrium, Prometrium may cause drowsiness or dizziness, and patients with peanut allergy should not use it as the formulation contains peanut oil; the labeling also notes risks including cardiovascular events and breast cancer associated with combined hormone therapy. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing. Commercially available Prometrium is separately regulated, and clinical decisions belong with the prescribing clinician.

Bi-Est is a compounded preparation combining estriol and estradiol in varying ratios and is not an FDA-approved product. According to NAMS (The Menopause Society), estriol is a naturally occurring estrogen metabolite. According to the FDA-approved prescribing information for estradiol, commercially available estradiol products are approved for the treatment of menopausal vasomotor symptoms, vulvovaginal atrophy, and related indications; estriol does not have an FDA-approved indication in the United States. According to the FDA-approved prescribing information for estradiol, estrogen therapies carry a boxed warning regarding risks of endometrial cancer (with unopposed estrogen in women with a uterus), cardiovascular events, and breast cancer. Compounded medications are not reviewed by FDA for safety or effectiveness before dispensing. Commercially available estradiol products are separately regulated, and clinical decisions about the use of any estrogen formulation belong with the prescribing clinician.